Related Experiment Videos
[Gene therapy for acute myocardial infarction]
1Department of Biochemistry and Molecular Pathophysiology, University of Occupational and Environmental Health, School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 24, 2001
Summary
Gene therapy offers a promising approach to improve outcomes after myocardial infarction. Combining recombinant proteins with gene transfer may provide effective local treatment for coronary artery injury, reducing side effects.
Area of Science:
- Cardiovascular Medicine
- Gene Therapy
- Regenerative Medicine
Context:
- Percutaneous coronary angioplasty with stent implantation (PTCA) is standard for myocardial infarction in Japan.
- Key goals for improved prognosis include inhibiting thrombosis and restenosis, salvaging ischemic myocardium, and suppressing adverse myocardial remodeling.
Purpose:
- To explore gene therapy as a potential treatment for myocardial infarction.
- To investigate the combined use of recombinant proteins and gene transfer for local therapy without systemic side effects.
Summary:
- Gene transfer of specific molecules can address pathological conditions post-myocardial infarction.
- A combined approach using recombinant proteins and anti-thrombotic gene therapy offers a practical local treatment strategy.
- Future therapies may involve angiogenesis gene therapy with endothelial progenitor cells or engineered tissue replacement.
Impact:
- Provides a potential therapeutic avenue for myocardial infarction patients.
- Highlights the feasibility of localized, targeted gene therapy to minimize systemic adverse effects.
- Outlines future directions in cardiovascular regenerative medicine, including tissue engineering.